Csanda E, Tárczy M
Institute of Neurology, Semmelweis Medical University, Budapest, Hungary.
J Neural Transm Suppl. 1987;25:105-13.
Selegiline is a useful adjuvant drug in the treatment of Parkinson's disease. In the early phase selegiline can be given in monotherapy. Its effect is not always sufficient to eliminate all the symptoms. In spite of this observation the administering of selegiline as monotherapy can be useful because in case of the immediate introduction of levodopa therapy untoward effects may appear in an early stage of treatment. In the course of substitution therapy selegiline successfully replaces about 30% of levodopa administered in "de novo" parkinsonian patients. Selegiline has a favourable beneficial effect in reducing the mild forms of response fluctuations. The addition of selegiline in such patients to the continuing substitution therapy prevents the development of more severe "on-off" manifestations. In severely disabled patients with irregular response swings or permanent akinesia the use of selegiline as an adjuvant drug cannot modify anymore the course of the disease.
司来吉兰是治疗帕金森病的一种有用的辅助药物。在早期阶段，司来吉兰可进行单一疗法给药。其效果并不总是足以消除所有症状。尽管如此，司来吉兰单一疗法给药仍可能有用，因为如果立即开始左旋多巴治疗，在治疗早期可能会出现不良反应。在替代疗法过程中，司来吉兰成功替代了“初发”帕金森病患者所服用左旋多巴的约30%。司来吉兰在减轻轻度形式的反应波动方面具有良好的有益效果。在此类患者中，将司来吉兰添加到持续的替代疗法中可防止更严重的“开 - 关”表现的发展。在有不规则反应波动或永久性运动不能的严重残疾患者中，使用司来吉兰作为辅助药物不再能改变疾病进程。
